Advertisement
UK markets closed
  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     
  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     
  • AIM

    789.87
    +6.17 (+0.79%)
     
  • GBP/EUR

    1.1622
    +0.0011 (+0.09%)
     
  • GBP/USD

    1.2525
    +0.0001 (+0.01%)
     
  • Bitcoin GBP

    48,602.02
    -1,615.94 (-3.22%)
     
  • CMC Crypto 200

    1,264.96
    -93.05 (-6.85%)
     
  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     
  • DOW

    39,512.84
    +125.08 (+0.32%)
     
  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     
  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     
  • DAX

    18,772.85
    +86.25 (+0.46%)
     
  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     

One of America's largest health insurers just stopped covering a main opioid painkiller

David Cordani
David Cordani

(Cigna CEO David Cordani is interviewed at the Reuters Health Summit 2014 in Washington April 1, 2014. REUTERS/Gary Cameron)

Cigna just made a move that could help curb opioid misuse.

Starting in 2018, the health insurer will no longer cover OxyContin, the branded version of the painkiller oxycodone. Cigna will still cover oxycodone alternatives to OxyContin.

The move is intended to cut back on the number of opioid prescriptions the insurer provides. In 2016, Cigna committed to lowering opioid use among its customers by 25% over the next three years.

"Our focus is on helping customers get the most value from their medications – this means obtaining effective pain relief while also guarding against opioid misuse," Cigna's chief pharmacy officer Jon Maesner said in a news release.

ADVERTISEMENT

More than 183,000 people died from overdoses related to prescription opioid painkillers like oxycodone, hydrocodone, fentanyl, and morphine over the last 15 years. In August, President Donald Trump declared the opioid crisis a "national emergency," though he has yet to formally designate it as such.

"We believe that patients should have access to FDA-approved products with abuse deterrent properties," Purdue Pharma, which makes the branded version of OxyContin said in a statement emailed to Business Insider. "Unfortunately, Cigna’s decision limits the tools prescribers can use to help address the opioid crisis as both products are formulated with properties designed to deter abuse."

NOW WATCH: I went on Beyoncé's 22-day diet — and I lost 15 pounds



More From Business Insider